Fish oil derivative may calm heart inflammation and stabilize plaques

NCT ID NCT07641257

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether icosapent ethyl, a purified fish oil medication, can reduce inflammation and improve heart structure in people with coronary artery disease. Researchers will follow 420 patients for one year, comparing those who receive standard care plus icosapent ethyl to those on standard care alone. They will measure blood markers of inflammation and use heart imaging to see if the drug helps stabilize fatty plaques and prevent harmful changes to the heart's shape.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
icosapent ethyl
What this could lead to
If it works, this could show that adding icosapent ethyl to standard care helps lower inflammation and stabilize heart plaques, potentially reducing future heart events.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also relatively small and short-term, so any benefits may not be confirmed or lasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES (ACS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.